Generated by AI
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies for gout, progressive kidney disease, and other disorders linked to elevated uric acid and abnormal purine metabolism. Its current pipeline includes programs for gout, autosomal dominant polycystic kidney disease, acute kidney injury associated with respiratory virus infections, and type 2 diabetic nephropathy. The company’s research centers on uric acid-lowering and xanthine oxidase-targeted approaches designed to address conditions ranging from rare kidney diseases to broader metabolic and renal disorders. Based in Calgary, Canada, XORTX Therapeutics Inc. operates as a biotechnology and pharmaceutical developer with an emphasis on advancing drug candidates through clinical development and commercialization in specialized disease areas.
Website3710 – 33rd Street NW
Calgary, AB, T2L 2M1
Canada
The latest articles about XRTX.
This post contains sponsored content and was created in collaboration with a third-party partner. Benzinga is a publisher and does not provide personalized investment advice or act as a broker or dealer. This content is
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs (NASDAQ:AIDX)
Tipranks Press Release.
Summary of Oct 12's posts. Generated by AI.
Summary of Oct 12's posts. Generated by AI.
Summary of Oct 12's posts. Generated by AI.
Investors talking about XRTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.